相关实验视频

Updated: Jun 15, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

抑制LSD1通过增强CD8⁺ T细胞响应性来提高采用T细胞治疗的疗效

Isabella Pallavicini¹, Teresa Maria Frasconi¹, Carlotta Catozzi¹

¹Istituto Europeo di Oncologia - IRCCS, Department of Experimental Oncology, Milan, Italy.

Nature communications

|August 27, 2024

概括

在采用T细胞治疗中,药理上抑制氨酸特异性基因组脱甲酶1A (LSD1) 增强了CD8+T细胞功能. 在临床前模型中,将LSD1抑制与抗PDL1治疗结合起来,可以消除瘤并促进长期存活.

科学领域:

免疫学免疫学免疫学
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
癌症研究癌症研究

背景情况:

氨酸特异性基因组脱甲酶1A (LSD1) 与抗瘤免疫有关.
目前尚不清楚LSD1在CD8+T细胞 (CTL) 分化和功能中的具体作用.

研究的目的:

在采用性T细胞疗法 (ACT) 中研究药理学LSD1抑制对CTLs的影响.
评估将LSD1抑制与抗PDL1治疗结合用于增强抗瘤反应的疗效.

主要方法:

在ACT中使用的CTL中对LSD1的药理抑制.
在雌性小鼠中的临床前模型,包括黑色素瘤模型.
组合疗法包括抗PDL1治疗和基于LSD1抑制的ACT.

主要成果:

在CTL中LSD1抑制导致显著的表型和功能性改变,在临床前模型中增强抗瘤免疫力.
对抗PDL1治疗和基于LSD1抑制的ACT的结合导致了完全的瘤根除.
这种组合疗法实现了长期的无瘤生存,优于单剂疗法.

结论:

调节LSD1活动改善了ACT产生的抗瘤反应.
将LSD1抑制与抗PDL1治疗相结合,为克服当前免疫疗法和表观遗传疗法的局限性提供了一个有希望的策略.
这些发现支持在癌症治疗中对LSD1调制的临床评估.

更多相关视频

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Published on: May 14, 2012

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Cell-mediated Immune Responses

Cell-mediated Immune Responses